Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Baylor College of Medicine
Eastern Cooperative Oncology Group
Karyopharm Therapeutics Inc
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Haihe Biopharma Co., Ltd.
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Adela, Inc
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istituto Oncologico Veneto IRCCS
Turning Point Therapeutics, Inc.
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Young Adult Survivors United
AVM Biotechnology Inc
Centre Leon Berard
Hospices Civils de Lyon
Washington University School of Medicine
Essen Biotech
Institut Bergonié
Region Skane
National Cancer Centre, Singapore
University Health Network, Toronto
IGM Biosciences, Inc.